19 results about "CD68" patented technology

The application belongs to the technical field of biotechnology, and particularly relates to a marker for prognosis evaluation of acute myeloid leukemia and application thereof, wherein the marker is HCK-positive mono-like cells, the HCK-positive mono-like cells are determined by co-positivity of antigens CD163, antigen CD68, antigen FCN1 and antigen HCK, and the application provides a marker with high sensitivity, strong specificity and good universality, which is used for detecting adult acute myeloid leukemia bone marrow or peripheral blood samples, so as to assist in judging the clinical prognosis of patients with acute myeloid leukemia.

The invention discloses a method for detecting non-target cells in amniotic epithelial cells, which comprises reagents for detecting one or more of the following gene markers: FCGBP, RNASE6, DAB2, STAB1, RAB3IL1, CSF1R, CD68, CD209, EGFL7, LGALS2, LILRB4, HLA-DMB, HLADMA, CD74, ANPEP, CD44, CCR7, CD3G, CD3D, CD27, CD5, SPOCK2, TCF7, GZMH, KLRC2 and the like. Wherein the non-target cells are selected from macrophage-like cells, monocyte-like cells, T cell-like cells, NK cell-like cells, myeloid-like cells and neutrophil-like cells, a detection method is provided for quality control of the amniotic epithelial cells, and guidance is also provided for a cell product preparation process.

The application belongs to the technical field of medical treatment and discloses a cancer prognosis marker combination and application thereof, which comprises the following markers: CD68, PD-L1, PAN-CK, HLA-DR, CD45, CD11c and Collagen I. The cancer prognosis evaluation model trained by using the 7-marker combination exhibits superior prognosis accuracy compared to a model relying on high-dimensional multi-omics data. The application proposes a multiple immunohistochemistry (mIHC) cancer prognosis evaluation detection product based on the above-mentioned cancer prognosis marker combination. Satisfactory prognosis results are achieved by using only two five-marker combinations. The method exhibits high accuracy in predicting the survival of gastric cancer patients, so that it becomes a low-cost, high-benefit and scalable solution for other cancers.

The invention discloses an application of TRAF7 in screening of anti-lung injury drugs. In an LPS-induced A549 cell acute lung injury model, TRAF7 gene knock-down significantly aggravates cell apoptosis and inflammatory response, which shows that inflammatory factor release is increased, and cell injury is aggravated; and TRAF7 overexpression can obviously inhibit the pathological change. The result shows that the TRAF7 has a protection effect on alveolar epithelial cells, the expression level of the TRAF7 is in negative correlation with the in-vitro lung injury degree, and it is proved that the TRAF7 has a negative regulation effect in acute lung injury. In a mouse ALI model, TRAF7 overexpression can significantly reduce the total number of cells, the total protein content and the wet / dry weight ratio of lung tissue in bronchoalveolar lavage fluid (BALF), relieve the pathological injury score of the lung and inhibit LY6Gneutrophil and CD68 macrophage infiltration. The TRAF7 can effectively relieve LPS-induced pulmonary edema, vascular permeability increase and tissue inflammation, and the anti-inflammatory and tissue protection functions of the TRAF7 in an in-vivo model are verified.

The invention provides application of an adeno-associated virus overexpressing CTH in preparation of drugs for extravascular treatment of abdominal aortic aneurysm. When the adeno-associated virus overexpressing CTH is applied to the periphery of abdominal aortic aneurysm, fracture of elastic fibers of abdominal aorta can be reduced, collagen deposition can be reduced, infiltration of macrophages (CD68) can be reduced, secretion of matrix metalloproteinase can be reduced, degradation of extracellular matrixes can be reduced, and occurrence and development of AAA can be relieved.

The application relates to the field of biological medicine, in particular to an anti-CD68 antibody and preparation and application thereof, wherein the anti-CD68 antibody has heavy chain complementarity determining regions 1-3 as shown in SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3 respectively, and light chain complementarity determining regions 1 and 3 as shown in SEQ ID NO:4 and SEQ ID NO:5 respectively, and a light chain complementarity determining region 2 with LVS. Compared with the CD68 antibody proposed in the related art, the anti-CD68 antibody proposed in the application has stronger binding specificity to CD68 and lower reaction background, thereby realizing high-accuracy detection of CD68.

The present disclosure relates to methods of treating certain cancers with a Siglec-9 extracellular domain (ECD) or a Siglec-9 ECD fusion molecule, including cancers expressing high levels of CD163 and / or Siglec-9 in tumor or immune cells, and methods of identifying cancers responsive to a Siglec-9 ECD or Siglec-9 ECD fusion molecule, for example by determining the level of CD163 and / or Siglec-9, and in some embodiments also CD68 and / or sialic acid expression in tumor or immune cells.

The invention discloses a prognostic marker for bladder cancer and application of the prognostic marker. The prognostic marker for the bladder cancer comprises CD14T, CD68S, CD163T and S100A12S; wherein the CD14T and the CD163T respectively refer to CD14 and CD163 expressed in a bladder cancer tumor region, and the CD68S and the S100A12S respectively refer to CD68 and S100A12 expressed in a bladder cancer matrix region. The bladder cancer prognosis marker provided by the invention can be used for constructing a bladder cancer prognosis prediction model, and multi-queue verification proves that the model has a strong prediction capability on the postoperative survival condition of a BLC patient and is beneficial to postoperative risk assessment and clinical decision of the BLC patient.

The invention provides application of an adeno-associated virus overexpressing CBX3 in preparation of a medicine for extravascular treatment of abdominal aortic aneurysm. When the adeno-associated virus overexpressing CBX3 is applied to the periphery of abdominal aortic aneurysm, fracture of elastic fibers of abdominal aorta can be reduced, collagen deposition can be reduced, infiltration of macrophages (CD68) can be reduced, secretion of matrix metalloproteinase can be reduced, degradation of extracellular matrixes can be reduced, and occurrence and development of AAA can be relieved.

The application relates to the field of biotechnology and relates to immune monitoring and imaging, and particularly discloses a base editing ectopic kidney method and a spatial omics imaging monitoring method. The base editing ectopic kidney method comprises the following steps: extracting and screening cytidine deaminase conditional knockout engineered cells of base editing conditional knockout young mice; the cytidine deaminase conditional knockout engineered cells are implanted into a spontaneous immune disease mouse model characterized by nephritis, and an autoimmune-kidney generation model is established. The young mice of APOBEC3 base editing enzyme CD68 cell conditional knockout mice are used as a functional cell source, the cytidine deaminase is not translated, the young mice are suitable for ectopic kidney generation, and the time cost required by single cell amplification, breeding and screening in a traditional cell transplantation scheme is avoided, and the experimental process is greatly simplified.

The invention discloses application of CD44v9 positive M2 type macrophages in preparation of gastric adenocarcinoma diagnosis or treatment products, in the technical scheme provided by the invention, it is proved that the M2 type macrophages of CD68 + CD86-CD163 + can express CD44v9 through multiple fluorescent staining, human acute mononuclear leukemia cells (THP-1 cells) are subjected to in-vitro culture and are sequentially induced into M0 type macrophages and M2 type macrophages, and the M0 type macrophages and the M2 type macrophages can be used for diagnosing or treating gastric adenocarcinoma. Then, the expression conditions of the M0 type macrophage CD44v9 and the M2 type macrophage CD44v9 are observed, and the result shows that the M0 type macrophage and the M2 type macrophage which are induced by the THP-1 cell in vitro can express the CD44v9, and the expression level of the M2 type macrophage is higher than that of the M0 type macrophage CD44v9. Afterwards, after co-culture with gastric adenocarcinoma AGS cells in M2 macrophages infected and induced by over-expressed CD44v9 lentivirus, the proliferation, migration and invasion capabilities of the AGS cells are enhanced, and the epithelial-mesenchymal transition of the AGS cells and the expression of matrix metalloproteinases (MMP2 and MMP9) are promoted.

The application discloses application of GPER1 and CD68 as a prognostic marker in preparation of a hepatocarcinoma prognosis test kit. Researches of the application show that by detecting the expression of GPER1 in macrophages of hepatocarcinoma tissues, the survival prognosis of hepatocarcinoma patients can be more accurately predicted. Specifically, a double immunofluorescence staining combined with tyramide signal amplification technology is used to detect the co-expression proportion of GPER1 and CD68 in hepatocarcinoma tissues, and it is shown that the prediction effect of the hepatocarcinoma patients on overall survival and recurrence-free survival is better than the overall GPER1 expression of tumor tissues. Compared with the prior art (only immunohistochemical staining of GPER1 is performed on tumor tissues), the method can obtain more detailed and accurate information of the GPER1 protein expression mode, and the prediction effect on the survival of hepatocarcinoma patients is better; the method is simple and easy to operate, and ordinary technicians can complete the whole operation process.

The invention relates to a breast cancer prognosis related biomarker, a detection kit and a biochip, the breast cancer prognosis related biomarker is a fusion cell formed by fusing an epithelial tumor cell and a myeloid cell, and the fusion cell comprises an epithelial cell molecular marker and a myeloid cell molecular marker; wherein the epithelial cell molecular marker comprises at least one of EPCAM and PanCK; the myeloid cell molecular marker comprises at least one of CD14 and CD68; the biomarker is used for breast cancer metastasis risk assessment. The liquid biopsy marker has the beneficial effects that the liquid biopsy marker for the metastasis risk of the breast cancer patient is provided and can be used as an independent prognosis index of the breast cancer metastasis risk.

This invention discloses the application of mRNA biomarkers in the early diagnosis of lung signet ring cell carcinoma and a kit. The biomarkers are a combination of C1QA, CRISPLD2, ROBO4, SPARCL1, SFTPB, LAMC3, FN1, EMP1, CD68, THBS1, PRG4, ICAM1, PODXL, KDM6B, ENPP2, KLF10, and THBD. This invention uses FFPE cancer tissue from patients clinically diagnosed with primary lung signet ring cell carcinoma using existing detection methods as samples, and adjacent normal tissue as control samples. RNA sequencing technology is used to detect the mRNA expression profiles of cancer tissue and control tissue. Statistical and machine learning methods are applied to identify 17 differentially expressed mRNA biomarkers. Based on these 17 biomarkers, a risk scoring model with high sensitivity and specificity is constructed. The model has a sensitivity >75% and a specificity >89% for the diagnosis of early lung signet ring cell carcinoma.

Multispecific constructs, e.g., bispecific constructs, which comprise an anti-B cell binding arm that specifically binds to a B-cell-specific cell surface marker such as CD20, CD19, CD21, CD24, or CD38, and a second binding arm that specifically binds to CD68 protein, and optionally at least one additional binding arm, wherein the multispecific constructs bind specifically to naïve B cells which express transcription factor ARID3a. Methods of using the multispecific constructs to treat autoimmune disorders and / or diseases including but not limited to Systemic lupus erythematosus (SLE), and SLE flare-ups.

This invention relates to an anti-human CD68 monoclonal antibody, its preparation method, and its applications. The amino acid sequences of the heavy chain complementarity-determining regions (CDR1, CDR2, and CDR3) of the anti-human CD68 monoclonal antibody include the sequences shown in SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3, respectively, and the amino acid sequences of the light chain complementarity-determining regions (CDR1, CDR2, and CDR3) include the sequences shown in SEQ ID NO.4, SEQ ID NO.5, and SEQ ID NO.6, respectively. This invention develops and prepares a highly specific and affinity-based anti-human CD68 monoclonal antibody with good anti-interference ability, wide applicability, and is suitable for high-specificity, high-accuracy, and high-sensitivity detection of CD68, especially for immunohistochemical detection.

The invention discloses application of a maravil and CCL5 neutralizing antibody to treatment of sepsis-related encephalopathy, and belongs to the field of medicinal chemistry. In-vivo experiments prove the novel application of the CCR5 antagonist malaviif and the CCL5 neutralizing antibody in treatment of sepsis-related encephalopathy (SAE), the survival rate of sepsis mice can be remarkably increased to 60% or above from about 30%, and anxiety-like behaviors and learning and memory dysfunctions of the mice can be effectively improved; according to the core mechanism, by inhibiting CCL5-CCR5 signal channels, pathological damage of hippocampal neurons is relieved, the level of key neuroinflammatory factors (IL-6, IL-1beta, CD68 and HMBG-1) is reduced, and by protecting dendritic spine density and synaptic related protein expression, abnormal synaptic phagocytosis of microglia is inhibited, so that comprehensive protection on the structures and functions of nerve synapses is achieved, and the application prospect is wide. And a verified brand-new target spot and an effective strategy are provided for clinical SAE treatment.

In the invention, mRNA of CXCL5, CD68, MATN1, SERPING1, SNCG, VTN, FBXO4 and SYTL4 genes, or proteins coded by the genes, show different expression levels between radiation-resistant colorectal cancer cells and radiation-sensitive colorectal cancer cells, and are closely related to the reduction of the survival rate in colorectal cancer patients. Therefore, according to the present invention, an agent for measuring the expression level of mRNA of a gene selected from the group consisting of CXCL5, CD68, MATN1, SERPING1, SNCG, VTN, FBXO4, and SYTL4 or a protein encoded by the gene effectively diagnoses radiation resistance in colorectal cancer or predicts radiation therapy for colorectal cancer. This makes it possible to determine whether to perform radiation therapy and the optimal radiation dose, thereby improving the efficiency and outcome of radiation therapy for colorectal cancer.

The invention relates to a construction method and application of a conditional knockout mouse model for studying the influence of a CLCF1 gene on cortical bone development. GRNA, Cas9 mRNA and a targeting vector are microinjected into a fertilized egg of a C57BL / 6J mouse, the fertilized egg after injection is transplanted to a pseudo-pregnant female mouse, and an F0-generation mouse is produced; the method comprises the following steps: hybridizing a positive F0 generation mouse which is subjected to correct homologous recombination at a target site of the CLCF1 gene with a wild type mouse to obtain a flox heterozygote mouse of the CLCF1 gene; the CLCF1 gene flox heterozygote mice are subjected to mutual mating, and CLCF1 gene flox homozygote mice are obtained; a CLCF1 gene flox homozygote mouse and a Cd68-Cre tool mouse are subjected to mating, a mouse with the genotype of CLCF1flox / flox and carrying Cd68-Cre is obtained, and the mouse is the target CLCF1 conditional gene knockout mouse model. The CLCF1 conditional gene knockout mouse model disclosed by the invention is a powerful tool for researching functions of the CLCF1 gene. Meanwhile, the model also lays a solid foundation for simulating skeletal system diseases and screening prevention and treatment drugs for bone mass reduction, skeletal atrophy or dysplasia, and provides an important experimental platform.